203 results
6-K
EX-99.1
BLU
Bellus Health Inc
28 Jun 23
GSK completes acquisition of BELLUS Health
11:05am
company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section … patients suffer from chronic cough, with 10 million patients globally and 6 million in the United States (US) and European Union (EU) suffering from RCC
6-K
EX-99.1
BLU
Bellus Health Inc
16 Jun 23
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
4:21pm
of refractory chronic cough (“RCC”). Camlipixant, the Company’s lead asset, is an investigational P2X3 receptor antagonist for the treatment of RCC, which
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
) for the treatment of refractory chronic cough (“RCC”). Camlipixant, the Company’s lead asset, is an investigational P2X3 receptor antagonist … the potential to be a breakthrough in the RCC treatment landscape.
Chronic cough is defined as a cough lasting longer than eight weeks. When the cause
6-K
EX-99.1
BLU
Bellus Health Inc
16 May 23
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
5:04pm
the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC
6-K
EX-99.2
4w70y9x5okkbmrl9d8gn
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
6-K
EX-99.1
q3i5 kxi9
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
6-K
EX-99.1
27e46e
26 Apr 23
BELLUS Health Announces Meeting Updates
6:00pm
6-K
EX-99.1
wflm6mn6vbn4iak59
18 Apr 23
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
6:02am
6-K
EX-99.1
d8m0rtdkk
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
6-K
EX-99.1
v726t6 ar
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.1
h7gvbegal87
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.2
4nnspgxcc var
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
4ft0b
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
0rs0g2ot7377s48m
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
jlglv
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
h6qt97
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
6-K
EX-99.1
a4splr8vrzc emrowv
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
6-K
EX-99.1
ls7ym0x0iwdd 32vdbr
6 Sep 22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
7:00am
F-10
kjg64rkaitjui c9l4b
26 Aug 22
Registration of securities (Canada)
4:48pm